Exact Sciences Corporation

Financials

Total assets 4.93 B6.68 B6.23 B6.47 B5.93 B5.86 B Total liabilities 2.1 B3.3 B3.18 B3.33 B3.53 B3.46 B Total equity 2.82 B3.39 B3.04 B3.15 B2.4 B2.4 B Total liabilities & shareholders' equities 4.93 B6.68 B6.23 B6.47 B5.93 B5.86 B Total debt 1.34 B2.18 B———— Net debt -495.87 M1.15 B————

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer. In November 2025, Abbott Laboratories agreed to acquire Exact Sciences in a deal worth roughly $21 billion.

EXAS

Financials

Exact Sciences Corporation

Haberler

Exact Sciences stock hits 52-week high at $103.55

Exact Sciences hissedarları Abbott ile birleşmeyi onayladı

Exact Sciences shareholders approve merger with Abbott Laboratories

Exact Sciences hissedarları Abbott satın almasını onayladı

Exact Sciences Q4 Earnings Match Estimates, Revenues Beat, Stock Up

Rekabet Kurulu- Son Kurul Kararları

CSLLY vs. EXAS: Which Stock Is the Better Value Option?

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates

Soft Start For $10B-Plus M&A Deals In 2026

Medicare çok kanserli erken tespit testleri için kapsam yolu oluşturdu

Medicare coverage pathway established for multi-cancer detection tests